A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening

Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subje...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 48; no. 3; pp. 367 - 374
Main Authors DANJOU, P, PATY, I, FRUNCILLO, R, WORTHINGTON, P, UNRUH, M, CEVALLOS, W, MARTIN, P
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.09.1999
Blackwell Science
Blackwell Science Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. Results No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. Conclusions The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration.
AbstractList To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double-blind to 36 healthy subjects under standardized conditions in a six-period, incomplete-block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration.
Aims  To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods  Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. Results  No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. Conclusions  The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration.
Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. Results No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. Conclusions The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration.
Author Paty
Cevallos
Worthington
Fruncillo
Martin
Danjou
Unruh
Author_xml – sequence: 1
  givenname: P
  surname: DANJOU
  fullname: DANJOU, P
  organization: Wyeth-Ayerst Research, Paris, France
– sequence: 2
  givenname: I
  surname: PATY
  fullname: PATY, I
  organization: Wyeth-Ayerst Research, Paris, France
– sequence: 3
  givenname: R
  surname: FRUNCILLO
  fullname: FRUNCILLO, R
  organization: Wyeth-Ayerst, Radnor, United States
– sequence: 4
  givenname: P
  surname: WORTHINGTON
  fullname: WORTHINGTON, P
  organization: Wyeth-Ayerst Biostatistics, Slough, United Kingdom
– sequence: 5
  givenname: M
  surname: UNRUH
  fullname: UNRUH, M
  organization: Wyeth-Ayerst, Radnor, United States
– sequence: 6
  givenname: W
  surname: CEVALLOS
  fullname: CEVALLOS, W
  organization: Wyeth-Ayerst, Radnor, United States
– sequence: 7
  givenname: P
  surname: MARTIN
  fullname: MARTIN, P
  organization: Wyeth-Ayerst, Radnor, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1922450$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10510148$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v1DAQhi1URLeFv4B84JowtuN8SAiprPioVAkOcLZmHbvrxbGjOGXbnpD4p_wSnG5Vyo2TrZnnnRm97wk5CjEYQiiDkkFVv96VTNSy4IzLknVdVwIAr8rrJ2T10DgiKxBQF5JLdkxOUtoBMMFq-YwcM5AMWNWuyHRGdRxGnFyKgUZL562hk0muv0JPjbVGz2mp36I3o88Mhp7eRj-63gzURu_j3oVLiv3ggkvzhLPLlKRzpPz3z19bujE2TobiHr-bkNHn5KlFn8yL-_eUfPvw_uv6U3Hx-eP5-uyi0LKuqmJj0NjaYsfaFnmtBYgOmrqrQEiJ0GoDDVTAhcSm3whsWsMbZLppem3aBsUpeXuYO15tBpOLIR_n1Ti5AacbFdGpfzvBbdVl_KF4tkawNg9oDwP0FFOajH3QMlBLDmqnFrvVYrdaclB3OajrLH35ePcj4cH4DLy6BzBp9HbCoF36y3WcVxIy9uaA7Z03N_-9X71bf8kf8QeK06gS
CODEN BCPHBM
CitedBy_id crossref_primary_10_1520_JFS2002357
crossref_primary_10_1016_j_sleep_2018_06_011
crossref_primary_10_1592_phco_27_1_89
crossref_primary_10_1002_hup_980
crossref_primary_10_1177_875512250101700202
crossref_primary_10_2165_11312920_000000000_00000
crossref_primary_10_5665_sleep_1996
crossref_primary_10_1097_00045391_200305000_00005
crossref_primary_10_1007_s13311_012_0148_3
crossref_primary_10_3389_fnins_2022_893015
crossref_primary_10_1002_hup_500
crossref_primary_10_1007_s00213_012_2756_3
crossref_primary_10_1177_089719000001300409
crossref_primary_10_1002_hup_986
crossref_primary_10_1126_scitranslmed_3005213
crossref_primary_10_1046_j__5251_2001_01520_x
crossref_primary_10_1586_ern_11_197
crossref_primary_10_1002_1099_1166_200008_15_8_704__AID_GPS183_3_0_CO_2_S
crossref_primary_10_1093_sleep_zsy258
crossref_primary_10_1002_hup_310
crossref_primary_10_1016_j_jsmc_2008_03_001
crossref_primary_10_1016_j_jsmc_2010_09_002
crossref_primary_10_1016_j_jsmc_2010_08_006
crossref_primary_10_1007_s11910_003_0074_1
crossref_primary_10_1177_1941738117743205
crossref_primary_10_1080_13803395_2014_928268
crossref_primary_10_1111_jnc_14055
crossref_primary_10_1016_j_sleep_2003_06_005
crossref_primary_10_1016_j_sleep_2015_05_021
crossref_primary_10_1016_j_pharmthera_2005_04_014
crossref_primary_10_1002_bdd_773
crossref_primary_10_1111_j_1742_1241_2001_tb11050_x
crossref_primary_10_1016_S0140_6736_01_06656_9
crossref_primary_10_1056_NEJMra012893
crossref_primary_10_1053_smrv_2000_0126
crossref_primary_10_1080_10401230500464711
crossref_primary_10_2165_00002018_200528040_00003
crossref_primary_10_1002_hup_282
crossref_primary_10_1097_HTR_0b013e3181c1d1e1
crossref_primary_10_1097_00004714_200212000_00007
crossref_primary_10_1016_j_csm_2011_03_009
crossref_primary_10_2165_00044011_200525120_00002
crossref_primary_10_2165_00003088_200443040_00002
crossref_primary_10_2165_00023210_200519010_00008
crossref_primary_10_2165_00023210_200418050_00003
crossref_primary_10_1016_S0149_2918_00_83024_6
crossref_primary_10_1345_aph_1A086
crossref_primary_10_1053_jhep_2002_30957
crossref_primary_10_1345_aph_1A040
crossref_primary_10_1177_0269881109106898
crossref_primary_10_1016_S0749_0690_03_00044_2
crossref_primary_10_1177_0269881111408954
crossref_primary_10_1037_1064_1297_11_4_259
crossref_primary_10_2165_00002018_200326040_00004
crossref_primary_10_1185_030079908X273327
crossref_primary_10_1111_j_1365_2125_2008_03331_x
crossref_primary_10_2165_00003495_200059040_00014
crossref_primary_10_1111_j_1742_1241_2001_tb10973_x
crossref_primary_10_1093_sleep_zsy153
crossref_primary_10_1093_sleep_zsz241
crossref_primary_10_1016_S1389_9457_99_00006_4
crossref_primary_10_1517_14656566_5_7_1573
crossref_primary_10_2165_00023210_200013030_00005
crossref_primary_10_1517_13543784_9_4_841
crossref_primary_10_1002_hup_216
crossref_primary_10_1016_j_jsmc_2006_06_010
Cites_doi 10.1097/00004714-199604000-00007
10.1016/S0009-9236(98)90139-4
10.1002/ddr.430330107
10.1007/BF02245455
10.1159/000137913
10.3928/0048-5713-19870701-06
10.1159/000137794
10.1017/S0033291700014379
10.1111/j.1365-2125.1990.tb03798.x
10.1016/0014-2999(96)00510-9
10.1093/sleep/14.5.408
10.2165/00003495-199040020-00008
10.1016/0924-9338(96)80094-0
10.3109/03602538308991391
10.1111/j.1471-4159.1984.tb09721.x
10.1111/j.1527-3458.1997.tb00324.x
10.1111/j.1365-2125.1980.tb01745.x
10.1002/j.1552-4604.1994.tb02002.x
10.1007/BF00735818
10.1007/BF00178503
10.1007/BF00265947
ContentType Journal Article
Copyright 1999 INIST-CNRS
1999 Blackwell Science Ltd 1999
Copyright_xml – notice: 1999 INIST-CNRS
– notice: 1999 Blackwell Science Ltd 1999
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1046/j.1365-2125.1999.00024.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2125
EndPage 374
ExternalDocumentID 10_1046_j_1365_2125_1999_00024_x
10510148
1922450
BCP024
Genre article
Comparative Study
Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
08R
AAJUZ
AAPBV
AAUGY
AAVGM
ABCVL
ABHUG
ABPTK
ABWRO
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
AKALU
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-c5644-beaef6fa9188a26c3039076940355a08ce07040235a7db3a78e27a1c77dce87a3
IEDL.DBID RPM
ISSN 0306-5251
IngestDate Tue Sep 17 21:18:04 EDT 2024
Fri Aug 23 01:27:17 EDT 2024
Sat Nov 02 11:54:55 EDT 2024
Sun Oct 29 17:07:47 EDT 2023
Sat Aug 24 00:57:24 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Human
Pharmacokinetic pharmacodynamic relationship
Agonist
Healthy subject
Psychotropic
Memory
Gabaergic agonist
Single dose
Hypnotic
Cognition
Residual effect
Blood
Zaleplon
Blood plasma
Awakening
Reaction time
Zolpidem
Clinical trial
Response latency
Sedative
Pharmacokinetics
Gabaergic receptor A
Comparative study
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5644-beaef6fa9188a26c3039076940355a08ce07040235a7db3a78e27a1c77dce87a3
OpenAccessLink https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00024.x
PMID 10510148
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2014318
crossref_primary_10_1046_j_1365_2125_1999_00024_x
pubmed_primary_10510148
pascalfrancis_primary_1922450
wiley_primary_10_1046_j_1365_2125_1999_00024_x_BCP024
PublicationCentury 1900
PublicationDate September 1999
PublicationDateYYYYMMDD 1999-09-01
PublicationDate_xml – month: 09
  year: 1999
  text: September 1999
PublicationDecade 1990
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: London
– name: England
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 1999
Publisher Blackwell Science Ltd
Blackwell Science
Blackwell Science Inc
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell Science
– name: Blackwell Science Inc
References 1990; 30
1984; 42
1993; 45
1976; 47
1982; 17
1991; 14
1994; 114
1995; 10
1976
1969; 55
1995
1996; 13
1997; 3
1996; 16
1998; 21
1998; 64
1987; 17
1978; 8
1979
1983; 14
1996; 11
1990; 40
1986; 88
1991; 41
1980; 10
1987
1994; 34
1994; 33
1985
1996; 313
1983; 26
1983; 27
1989
e_1_2_5_26_2
e_1_2_5_24_2
e_1_2_5_25_2
e_1_2_5_22_2
e_1_2_5_23_2
e_1_2_5_20_2
Tobler I (e_1_2_5_34_2) 1991; 41
e_1_2_5_21_2
Berlin I (e_1_2_5_35_2) 1996; 13
e_1_2_5_28_2
e_1_2_5_29_2
Sternberg S (e_1_2_5_27_2) 1969; 55
Dement WC (e_1_2_5_2_2) 1982; 17
e_1_2_5_40_2
Fry J (e_1_2_5_39_2) 1998; 21
e_1_2_5_14_2
e_1_2_5_37_2
e_1_2_5_13_2
e_1_2_5_38_2
e_1_2_5_9_2
e_1_2_5_16_2
e_1_2_5_8_2
e_1_2_5_15_2
e_1_2_5_36_2
e_1_2_5_7_2
e_1_2_5_10_2
e_1_2_5_33_2
e_1_2_5_6_2
e_1_2_5_5_2
e_1_2_5_12_2
e_1_2_5_31_2
e_1_2_5_4_2
e_1_2_5_3_2
Johnson C (e_1_2_5_11_2) 1983; 26
e_1_2_5_18_2
e_1_2_5_17_2
e_1_2_5_19_2
e_1_2_5_30_2
Schechter BR (e_1_2_5_32_2) 1996; 11
References_xml – volume: 88
  start-page: 426
  year: 1986
  end-page: 433
  article-title: Chronic use of benzodiazepines and psychomotor and cognitive test performance.
  publication-title: Psychopharmacology (Berl )
– start-page: 116
  year: 1995
– volume: 27
  start-page: 70
  year: 1983
  end-page: 75
  article-title: Pharmacokinetics of benzodiazepine hypnotics.
  publication-title: Pharmacology
– volume: 17
  start-page: 446
  year: 1987
  end-page: 453
  article-title: Epidemiology of sleep disorders.
  publication-title: Psychiatr Ann
– volume: 3
  start-page: 207
  year: 1997
  end-page: 224
  article-title: A review of the preclinical development of Zaleplon, a novel non‐benzodiazepine hypnotic for the treatment of insomnia.
  publication-title: CNS Drug Reviews
– volume: 11
  start-page: 215
  year: 1996
  end-page: 305
  article-title: Next day effects after night‐time treatment with zolpidem.
  publication-title: Eur J Psychiatry
– start-page: 1257
  year: 1979
  end-page: 1262
– volume: 30
  start-page: 463
  year: 1990
  end-page: 469
  article-title: Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 20 mg and placebo.
  publication-title: Br J Clin Pharmacol
– volume: 10
  start-page: 189
  year: 1980
  end-page: 209
  article-title: Psychomotor function and psychoactive drugs.
  publication-title: Br J Clin Pharmacol
– volume: 55
  start-page: 421
  year: 1969
  end-page: 457
  article-title: Memory scanning: mental processes revealed by reaction time experience.
  publication-title: Am Sci
– start-page: 1944
– volume: 42
  start-page: 221
  year: 1984
  end-page: 229
  article-title: Binding characteristics and interaction of depressant drugs with [35S]t‐butylbicyclophosphorothionate, a ligand that binds to the picrotoxin site.
  publication-title: J Neurochem
– volume: 114
  start-page: 138
  year: 1994
  end-page: 146
  article-title: . EEG, profile of intravenous zolpidem in healthy volunteers.
  publication-title: Psychopharmacology (Berl )
– start-page: 239
  year: 1976
  end-page: 244
– volume: 8
  start-page: 325
  year: 1978
  end-page: 329
  article-title: Factor analysis of a sleep evaluation questionnaire.
  publication-title: Psychol med
– volume: 33
  start-page: 39
  year: 1994
  end-page: 45
  article-title: CL 284, 846 [Zaleplon] a novel sedative–hypnotic. evaluation of its metabolites for pharmacological activity and .
  publication-title: Drug Dev Res
– start-page: 339
  year: 1985
  end-page: 379
– start-page: 163
  year: 1987
  end-page: 172
– volume: 40
  start-page: 291
  year: 1990
  end-page: 313
  article-title: Zolpidem a review of its pharmacodynamic and pharmacokinetics properties and therapeutic potential.
  publication-title: Drugs
– start-page: 265
  year: 1987
  end-page: 272
– volume: 14
  start-page: 408
  year: 1991
  end-page: 413
  article-title: Postmarketing surveillance of zopiclone insomnia: Analysis of 20.513 cases.
  publication-title: Sleep
– volume: 45
  start-page: 313
  year: 1993
  end-page: 320
  article-title: The effects of single doses of CL 284, 846, lorazepam and placebo on psychomotor and memory function in normal male volunteers.
  publication-title: Eur J Clin Pharmacol
– volume: 21
  start-page: 262
  year: 1998
  article-title: . A phase III, 28‐day, multicenter, randomized, double‐blind comparator‐ and placebo‐controlled, parallel‐group safety, tolerability, and efficacy study of 5, 10, and 20 mg, of zaleplon, compared with 10 mg, of zolpidem or placebo, in adult outpatients with insomnia.
  publication-title: Sleep
– volume: 14
  start-page: 251
  year: 1983
  end-page: 292
  article-title: Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.
  publication-title: Drug Metab Rev
– volume: 47
  start-page: 175
  year: 1976
  end-page: 182
  article-title: Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects—a review.
  publication-title: Psychopharmacology
– volume: 13
  start-page: 100
  year: 1996
  end-page: 106
  article-title: Comparisons of the effects of zolpidem and Triazolam on previous functions, psychomotor performances, and physical sway in healthy subjects.
  publication-title: J Clin Psychopharmacol
– start-page: 313
  year: 1989
  end-page: 31
– volume: 313
  start-page: 35
  year: 1996
  end-page: 42
  article-title: Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem.
  publication-title: Eur J Pharmacol
– volume: 10
  start-page: 129
  year: 1995
  end-page: 135
  article-title: Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunizatrepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.
  publication-title: Eur Psychiatry
– volume: 26
  start-page: 21
  year: 1983
  end-page: 137
  article-title: Rebound insomnia and rebound anxiety: a review.
  publication-title: Pharmacology
– start-page: 1537
  year: 1985
  end-page: 1553
– volume: 17
  start-page: 3
  year: 1982
  end-page: 38
  article-title: Rational basis for the use of sleeping pills.
  publication-title: Int Pharmacopsychiatry
– volume: 16
  start-page: 146
  year: 1996
  end-page: 157
  article-title: Zolpidem, Triazolam and Temazepam: behavioural and subject related effects in normal volunteers.
  publication-title: J Clin Psychopharmacol
– volume: 26
  start-page: 21
  year: 1983
  end-page: 137
  article-title: Sedative‐hypnotics and human performance.
  publication-title: Psychopharmacol
– volume: 64
  start-page: 553
  year: 1998
  end-page: 561
  article-title: Comparative kinetics and dynamics of zaleplon, zolpidem and placebo.
  publication-title: Clin Parmacol Ther
– volume: 34
  start-page: 335
  year: 1994
  end-page: 344
  article-title: . A placebo‐controlled evaluation of single, escalating doses of CL284, 846 (zaleplon), a non–benzodiazepine hypnotic.
  publication-title: J Clin Pharmacol
– start-page: 1983
– volume: 41
  start-page: 581
  year: 1991
  end-page: 583
  article-title: Effects on night‐time motor activity and performance in the morning after midazolam intake during the night.
  publication-title: Arzneimittelforschung
– volume: 11
  start-page: 215
  year: 1996
  ident: e_1_2_5_32_2
  article-title: Next day effects after night‐time treatment with zolpidem.
  publication-title: Eur J Psychiatry
  contributor:
    fullname: Schechter BR
– volume: 13
  start-page: 100
  year: 1996
  ident: e_1_2_5_35_2
  article-title: Comparisons of the effects of zolpidem and Triazolam on previous functions, psychomotor performances, and physical sway in healthy subjects.
  publication-title: J Clin Psychopharmacol
  contributor:
    fullname: Berlin I
– ident: e_1_2_5_36_2
  doi: 10.1097/00004714-199604000-00007
– ident: e_1_2_5_30_2
  doi: 10.1016/S0009-9236(98)90139-4
– ident: e_1_2_5_20_2
  doi: 10.1002/ddr.430330107
– ident: e_1_2_5_16_2
– ident: e_1_2_5_10_2
– ident: e_1_2_5_13_2
– ident: e_1_2_5_33_2
  doi: 10.1007/BF02245455
– ident: e_1_2_5_9_2
  doi: 10.1159/000137913
– ident: e_1_2_5_8_2
– ident: e_1_2_5_3_2
– ident: e_1_2_5_5_2
  doi: 10.3928/0048-5713-19870701-06
– ident: e_1_2_5_12_2
  doi: 10.1159/000137794
– ident: e_1_2_5_21_2
– ident: e_1_2_5_28_2
  doi: 10.1017/S0033291700014379
– ident: e_1_2_5_31_2
  doi: 10.1111/j.1365-2125.1990.tb03798.x
– ident: e_1_2_5_38_2
  doi: 10.1016/0014-2999(96)00510-9
– ident: e_1_2_5_6_2
– ident: e_1_2_5_24_2
– ident: e_1_2_5_15_2
  doi: 10.1093/sleep/14.5.408
– ident: e_1_2_5_22_2
  doi: 10.2165/00003495-199040020-00008
– ident: e_1_2_5_40_2
– volume: 41
  start-page: 581
  year: 1991
  ident: e_1_2_5_34_2
  article-title: Effects on night‐time motor activity and performance in the morning after midazolam intake during the night.
  publication-title: Arzneimittelforschung
  contributor:
    fullname: Tobler I
– ident: e_1_2_5_37_2
  doi: 10.1016/0924-9338(96)80094-0
– ident: e_1_2_5_14_2
  doi: 10.3109/03602538308991391
– volume: 55
  start-page: 421
  year: 1969
  ident: e_1_2_5_27_2
  article-title: Memory scanning: mental processes revealed by reaction time experience.
  publication-title: Am Sci
  contributor:
    fullname: Sternberg S
– ident: e_1_2_5_17_2
  doi: 10.1111/j.1471-4159.1984.tb09721.x
– volume: 21
  start-page: 262
  year: 1998
  ident: e_1_2_5_39_2
  article-title: . A phase III, 28‐day, multicenter, randomized, double‐blind comparator‐ and placebo‐controlled, parallel‐group safety, tolerability, and efficacy study of 5, 10, and 20 mg, of zaleplon, compared with 10 mg, of zolpidem or placebo, in adult outpatients with insomnia.
  publication-title: Sleep
  contributor:
    fullname: Fry J
– ident: e_1_2_5_18_2
  doi: 10.1111/j.1527-3458.1997.tb00324.x
– ident: e_1_2_5_23_2
  doi: 10.1111/j.1365-2125.1980.tb01745.x
– volume: 26
  start-page: 21
  year: 1983
  ident: e_1_2_5_11_2
  article-title: Sedative‐hypnotics and human performance.
  publication-title: Psychopharmacol
  contributor:
    fullname: Johnson C
– ident: e_1_2_5_19_2
  doi: 10.1002/j.1552-4604.1994.tb02002.x
– ident: e_1_2_5_26_2
  doi: 10.1007/BF00735818
– ident: e_1_2_5_7_2
– ident: e_1_2_5_25_2
  doi: 10.1007/BF00178503
– ident: e_1_2_5_29_2
  doi: 10.1007/BF00265947
– ident: e_1_2_5_4_2
– volume: 17
  start-page: 3
  year: 1982
  ident: e_1_2_5_2_2
  article-title: Rational basis for the use of sleeping pills.
  publication-title: Int Pharmacopsychiatry
  contributor:
    fullname: Dement WC
SSID ssj0013165
Score 1.9945704
Snippet Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at...
To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at...
Aims  To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration...
SourceID pubmedcentral
crossref
pubmed
pascalfrancis
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 367
SubjectTerms Acetamides - administration & dosage
Acetamides - adverse effects
Adult
Biological and medical sciences
Double-Blind Method
Drug Administration Schedule
Female
Humans
hypnotic
Hypnotics and Sedatives - administration & dosage
Hypnotics and Sedatives - adverse effects
Hypnotics. Sedatives
Male
Medical sciences
Memory - drug effects
Neuropharmacology
Original
Pharmacology. Drug treatments
Psychology. Psychoanalysis. Psychiatry
Psychomotor Performance - drug effects
Psychopharmacology
Pyridines - administration & dosage
Pyridines - adverse effects
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
residual effects
sedative
zaleplon
Zolpidem
SummonAdditionalLinks – databaseName: Wiley Online Library - Core collection (SURFmarket)
  dbid: DR2
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp0Lp-7FJE3QoOcXLypYs-5imCaHQspQEcjMjWSJlg70kG9LsKZB_ml_SGcn7cOihlN6MbfkxHmk-Wd98w9gnYQqT-8wkdS0hkTXIxJROJMYaK4H0TizlDn_7nh-fyq9n6qzjP1EuTNSHWP5wo54Rxmvq4GBiFZJRULddMLQwQlPKHclOYrwZEp4UmSZ215cf6WpBQYSqkoSQce6lREfq6RY4_3ihXqR6NoUrNJqP1S7WwtVjKuU6xA0x6ugFmyzeLlJTJsPrmRna-SPhx__z-i_Z8w7K8v3oe6_YE9e8ZrvjqIV9u8dPVqldV3t8l49XKtm3b9jlPrfLGoi89RyRKMe5f0gO4x3NhPbPMYRNL_AcaGo-by9CSVvu0X_bG4y7HHryv1zxWcvTh7v7c24cInLH4QYmjn7_vGWnR4cnB8dJVwAisQpxWmIcOJ97KEVRQJpbDLc4l89LOUKUBKPCOhywJCn2gK5NBrpwqQZhtcbvUWjI3rGNpm3cB8al0cpnVpnAbLWqdLrIc5zr-Qw8pMWAicXHrqZR56MK6_OSctnI1BWZuiJTV8HU1a8B2-55xaphicBIjQbsfXSOtSvSECjxbrrnNssTSOy7f6T5eR5Ev1MSYhTYUgWv-OuHrD4fjHFj8x_bbbGnUaiCWHUf2cbs8tptIwybmZ3QwX4D-0woag
  priority: 102
  providerName: Wiley-Blackwell
Title A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
URI https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2125.1999.00024.x
https://www.ncbi.nlm.nih.gov/pubmed/10510148
https://pubmed.ncbi.nlm.nih.gov/PMC2014318
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEB2SnAql9LtqmjCHklMUW9KuVjqmpiEUUkxJIDcxu9oloY4kGpd8_PrOrqTY7qn0ZmTJFvvGnjfaN28APie60LnLdFzXgmJRk4h1aZNYG20Eeb8T43uHz77npxfi26W83AI59sIE0b7R10fN4uaoub4K2sruxkxGndhkfjZLvSldUky2YZsDdCzRx62DJMyP9FyYqyyZDPKdYSsziLo4qfsuPe9UySmq96IOwemnAK2lp-cd3fJKuX7ExVqO-ls_uc5rQ2I6eQkvBkaJx_2dv4It27yGg3lvSf1wiOerDqvbQzzA-cqs-uENdMdonkYRYuuQCSFyCR56tHBQe_jjj5xJugWfQ02Nj-0iTJZFx2HU3nH6Q9pw4UWJyxZTvEJtmRZbpDv6af0zmLdwcfL1fHYaD1MYYiOZLMXaknW5ozIpCkpzwzmPC-q8FFOmKjQtjOV_DeFtc0jVOiNV2FRRYpTi9SkUZe9gp2kb-wFQaCVdZqQO8lIjS6uKPOeCy2XkKC0iSMbFr7rebKMKm-TCN5R57CqPXeWxqwJ21X0EexsorS4smZ3IaQTve7DWPrGHOgK1AePTCd5xe_MdDsTgvD0EXgQyAP7PN1l9mc35xcf__sZdeNb7RXhx2yfYWf76bfeYDS31PtcBP9L98Bv4A0fKB2g
link.rule.ids 230,315,730,783,787,888,1378,27938,27939,46308,46732,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEB1Remilqt-0ptDOoeKEk_hj7fURoqK0JSiHUHGzdtdrgQi2VYIo-fXM7tok4dT2Zvkz9j573mTfvAH4GkgukzKSflHEwo8LEfsy04EvlVSxMH4nytQOj0-S0Wn844ydbQDramGsaF_Ji141u-pVF-dWW9lcqX6nE-tPxsPQmNIFvP8EntL7Oki6JL2bPAhsB0nDhinPYkEr4GknM62si8K6qdMzXpUUpJwbtYWn6QO0EqBeNOKanlXpmlysRKnHCspVZmtD09Er-NXdlFOkXPZu5rKnFo_8Hv_5rl_Dy5as4oHb_AY2dPUW9ibO7fpuH6fL4q3rfdzDydIH--4dNAeoHrocYl0icU2k7N6Wf2ErJDHrFxSkmhntI6oCF_XMNq3FkhBa31JkRbFm8IsM5zWGeI5SE-PWKG7FpTZ_77yH06Nv0-HIbxs8-IoRD_OlFrpMSpEFnIswURROKVdPsnhALEgMuNL0QYqNI49ICxmJlOswFYFKU3rwPBXRFmxWdaU_AsYyZWWkmLTKVcUynfIkoVyujEQpQu5B0I1q3jgfj9zOv8emVs2AIjegyA0ocguK_I8Hu2vDvzwwI-LDBh58cChYOaPDkAfpGj4edjBm3utbaLStqXc7uh4wi6S__pH54XBCC9v_fcUv8Gw0HR_nx99Pfn6C586WwmjodmBz_vtG7xLpmsvP9hW7B7jFKGo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb5tAEB21qVRVqtLvlrZp51DlFGwDCyzH1K2VfiTikEhRL2h32VWiOIASR2n86zu7QIxzqnJDZm0-9sG88b55A_AlkFwmJpJ-WTLhs1IwX2Y68KWSignrd6Js7fD-QbJ3xH4ex8eDVl9OtK_k6aian4-q0xOnrWzO1bjXiY3z_WloTekCPm5KM34Ij-iZnfA-Ue8XEALXRdIyYsq14qAT8XQLmk7aRaHd1upZv0oKVK0jtYOo7QU0CFJPG3FJ98u0jS4GkequinLIbl14mj2DP_2FtaqUs9HVQo7U8o7n472u_DlsdqQVd9shL-CBrl7Cdt66Xt_s4OGqiOtyB7cxX_lh37yCZhfVbbdDrA0S50TK8l0ZGHaCEvv5koJVM6cxoipxWc9d81o0hNT6miIsijWjX4xxUWOIJyg1MW-N4lqcafs3z2s4mn0_nO75XaMHX8XEx3yphTaJEVnAuQgTRWGVcvYkYxNiQ2LClaYXE7POPCItZSRSrsNUBCpN6ebzVERvYKOqK_0OkMk0NpGKpVOwqjjTKU8SyulMJIwIuQdBP7NF0_p5FG4dntmaNQuMwgKjsMAoHDCKvx5srUFg9cWMCFA88eBti4TBL7Y48iBdw8jtAGvqvb6HZtyZe3cz7EHs0PTfJ1l8nea08f7eR_wMj_Nvs-L3j4NfH-BJ605hpXQfYWNxcaW3iHst5Cf3lP0DFSgq6g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comparison+of+the+residual+effects+of+zaleplon+and+zolpidem+following+administration+5+to+2+h+before+awakening&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Danjou%2C+P&rft.au=Paty%2C+I&rft.au=Fruncillo%2C+R&rft.au=Worthington%2C+P&rft.date=1999-09-01&rft.issn=0306-5251&rft.volume=48&rft.issue=3&rft.spage=367&rft_id=info:doi/10.1046%2Fj.1365-2125.1999.00024.x&rft_id=info%3Apmid%2F10510148&rft.externalDocID=10510148
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon